Bevacizumab

Cat. No. M6166

All AbMole products are for research use only, cannot be used for human consumption.

Size	Price	Availability	Quantity
5mg	USD 600 USD600	In stock

Free Delivery on orders over USD 500 Bulk Inquiry?

Bevacizumab is A humanized IgG1 monoclonal antibody that binds with high affinity and specificity to all VEGF-A.

Talanta. 2025 Apr 1;285:127431.

Biologically-driven RAFT polymerization-amplified platform for electrochemical detection of antibody drugs
Bevacizumab purchased from AbMole
Anal Chem. 2024 Jun 4;96(22):9278-9284.

Site-Directed Electrochemical Grafting for Amplified Detection of Antibody Pharmaceuticals
Bevacizumab purchased from AbMole
Anal Chem. 2023 Sep 19;95(37):14094-14100.

Amplification-Free Ratiometric Electrochemical Aptasensor for Point-of-Care Detection of Therapeutic Monoclonal Antibodies
Bevacizumab purchased from AbMole
EMBO Mol Med. 2022 May 9;14(5):e14844.

SARS‐CoV‐2 spike spurs intestinal inflammation via VEGF production in enterocytes
Bevacizumab purchased from AbMole

Cell Experiment
Cell lines	NSCLC cell lines
Preparation method	Six NSCLC cell lines were seeded (~2,000–5,000 cells per well, depending on cell type) onto 96-well plates. After 24 h of incubation, cells were treated with erlotinib (0–20 µmol/L), bevacizumab (0–20 ng/mL) or a combination of these agents (erlotinib 1 µmol/L; bevacizumab 10 ng/mL) for 72 h in serum-containing medium. The viability was determined by MTS assay (Promega, Madison, WI) according to the manufacturer’s instructions.
Concentrations	0–20 ng/mL
Incubation time	72 h

CAS Number	216974-75-3
Solubility (25°C)	Water PBS
Storage	Store at -20°C or -70°C. Avoid multiple freeze-thaws.

Related VEGFR/PDGFR Products
ABT-869 ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR.
Tivozanib (AV-951) Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively.
Axitinib Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.
Regorafenib Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively.
Nintedanib Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

Catalog